Charles Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. He has published extensively on antiviral and antibiotic drug transport and metabolism, and metabolic drug interactions. His current research focuses on the discovery and development of new molecules and formulations for long-acting parenteral administration for the treatment and prevention of HIV infection. He directs the Long-Acting/Extended Release Antiretroviral Research Resource Program, which provides advice and support to the World Health Organization, Unitaid, and more. He is Co-Director of the Johns Hopkins University Baltimore-Washington-India HIV Clinical Trials Unit and chairs the Antiretroviral Strategies committee of the AIDS Clinical Trials Group. He is the Chief Scientific Officer of the Institute for Clinical and Translational Research at John’s Hopkins and a member of the editorial board of 12 scientific journals.
At the completion of this educational session, learners will:
1. Understand the rationale for long-acting antiretroviral formulations for HIV treatment and prevention.
2. Know the pharmacology of nanoformulated cabotegravir, rilpivirine, and similar formulations.
3. Be able to explain the mechanism of anti-HIV activity of islatravir and lenacapavir.
4. Know the difference between erodable and non-erodable implant formulations.
This CME activity has approved for
AMA PRA Category 1 Credit™ for March 24, 2021 as a live activity. This activity will also be available as an enduring activity from March 25, 2021, through March 23, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Charles W. Flexner (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Advisory Board Member to Merck, and ViiV; Expert Witness for Gilead. Dr. Flexner will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation
Download Article PDF/Slides